507 studies found for:    Open Studies | "Melanoma"
Show Display Options
Rank Status Study
21 Recruiting Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Tremelimumab;   Drug: MEDI3617
22 Recruiting Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
Condition: Metastatic Melanoma
Intervention: Drug: Anti-B-RAF
23 Not yet recruiting Nivolumab Plus Radiotherapy in Advanced Melanoma
Condition: Melanoma
Interventions: Biological: Nivolumab;   Radiation: hypofractionned radiotherapy
24 Not yet recruiting Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Standard therapy or clinical trial;   Drug: Matched targeted therapy;   Drug: Trametinib and / or supportive care
25 Recruiting The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Condition: Melanoma
Intervention: Drug: Vemurafenib
26 Recruiting Cytogenetic Study of Ocular Melanoma
Condition: Choroidal Melanoma
27 Recruiting Radiotherapy & Combi in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Radiation: Palliative radiotherapy;   Drug: Dabrafenib and trametinib (combination)
28 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
29 Recruiting Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
Condition: Melanoma
Interventions: Biological: Dose 1;   Biological: Dose 2;   Biological: Dose 3;   Biological: Dose 4
30 Not yet recruiting A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: PLX3397
31 Recruiting Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Condition: Melanoma
Intervention: Biological: Escalating Doses
32 Recruiting Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib;   Drug: Atezolizumab
33 Recruiting Neurotropic Melanoma of the Head and Neck
Condition: Melanoma
Interventions: Other: Observation;   Radiation: Radiation Therapy
34 Not yet recruiting MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients
Condition: Melanoma
Interventions: Drug: Propranolol;   Drug: Placebo
35 Recruiting Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Condition: Melanoma
Interventions: Drug: High-dose Interferon alfa-2b;   Drug: Vemurafenib
36 Not yet recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
37 Recruiting A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Condition: Stage IV Melanoma
Intervention: Drug: pembrolizumab
38 Recruiting Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Condition: Melanoma
Intervention: Biological: tvs-CTL Vaccine
39 Recruiting Intratumoral Injections of LL37 for Melanoma
Condition: Melanoma
Interventions: Biological: LL37;   Other: Photographs
40 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.